SciELO - Scientific Electronic Library Online

 
vol.12 issue3Effect of selected anti-inflammatory drugs on the lethal actions of Leiurus quinquestriatus venomPharmacological characterization of rat paw edema induced by Cerastes gasperettii (cerastes) venom author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Journal of Venomous Animals and Toxins including Tropical Diseases

On-line version ISSN 1678-9199

J. Venom. Anim. Toxins incl. Trop. Dis vol.12 no.3 Botucatu  2006

http://dx.doi.org/10.1590/S1678-91992006000300004 

ORIGINAL PAPER

 

Optimization of antiscorpion venom production

 

 

Ozkan O.I; Adigüzel S.I; Ates C.I; Bozyigit I.I; Filazi A.II

IRefik Saydam Hygiene Center, Ankara, Turkey
IIDepartment of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ankara University, Ankara, Turkey

Correspondence to

 

 


ABSTRACT

The present study was carried out to produce highly efficient antivenom from a small number of telsons in a short time. Venom solution was prepared through maceration of telsons from Androctonus crassicauda (Olivier, 1807) collected in the Southeastern Anatolia Region, Turkey. Lethal dose 50% (LD50) of the venom solution injected into mice was 1 ml/kg (95% confidence interval; 0.8-1.3), according to probit analysis. Different adjuvants (Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, and 0.4% aluminium phosphate), at increasing doses and combined with venom, were subcutaneously injected into horses on days 0, 14, 21, 28, 35, and 42 of the experiment. Antivenom was collected from the immunized horses on days 45, 48, and 51 using the pepsin digestive method. The antivenom effective dose 50% (ED50) in mice was 0.5 ml (95% confidence interval; 0.40-0.58), according to probit analysis. It was concluded that 0.5 ml antivenom neutralized a venom dose 35-fold higher than the venom LD50. Thus, highly potent antivenom could be produced from about 238 telsons in 51 days.

Key words: scorpion, antivenom, Androctonus crassicauda.


 

 

INTRODUCTION

Scorpions are members of the order Scorpiones, class Arachnida, subgroup of Arthropoda (10). Within the 1,500 species defined so far, only 50 were stated to be dangerous to humans (12, 14). Lethal scorpions are mostly of the Buthidae family. Among these, the species belonging to Androctonus, Leiurus and Mesobuthus genera are considered the most significant in causing envenomations in Turkey (14).

In cases of envenomation by scorpion stings, it is often recommended that patients be treated with species-specific antivenom (1). Scorpion antivenom treatment, initially introduced in 1909, is still the only method used for therapy (6, 16). In Turkey, scorpion antivenom has been produced in Refik Saydam Hygiene Center (RSHC) since 1942 (17, 18).

Also in Turkey, venom obtained through maceration of telsons from A. crassicauda scorpions is used as an antigen for antivenom production; this antigen is applied against other scorpion species too (15, 17, 18). In such method, hyperimmunization of one horse requires venom from approximately 1,500-2,000 telsons in a period of 4-5 months (18). However, costs are rather high since both a great quantity of telsons and a long time are required to obtain antivenom. Therefore, this study was aimed at producing highly efficient antivenom in a shorter period of time using fewer telsons.

 

MATERIALS AND METHODS

Animals

Seventy-seven healthy male Swiss albino mice, 20±1 g, 6 weeks old, were used for determination of the venom LD50, the antivenom ED50, and the immune status of horses. Throughout the experiment, animals were kept in the experiment room under 22±2°C and 60±10% humidity. They were fed with commercial mouse pellets ad libitum.

Also, 5 local breed horses (300-400 kg), aged from 8 to 10 years, were used for the production of antivenom. During the hyperimmunization period, they were fed with barley and dried meadow grass.

Venom solution preparation

Venom solution was prepared by the method of maceration (3, 4, 7, 19) using 1,350 telsons (approximately 20 g) from A. crassicauda scorpions collected at the Southeastern Anatolia Region, Turkey. Telsons were ground to a fine powder and dissolved in physiologic saline solution (PSS – 0.9% sodium chloride solution) to 150 ml, resulting in a venom stock solution of 180 mg telsons/ml.

Determination of the Lethal Dose 50% (LD50)

Different doses (0.05, 0.1, 0.15, 0.2, 0.25, and 0.3 ml) of the venom stock solution were separated in 3-ml tubes, which had their volumes completed with PSS, resulting in the following concentrations: 3, 6, 9, 12, 15, and 15 mg/ml, respectively.

To determine the venom LD50, 35 mice were divided into 7 groups of 5 mice each. Then, 0.5 ml of a different concentration of the above-mentioned venom solutions was subcutaneously injected into each group. Mice in groups 1, 2, 3, 4, 5, and 6 received 1.5, 3, 4.5, 6, 7.5, and 9 mg venom, respectively. Control group was treated with 0.5 ml PSS, subcutaneously. Following treatment with venom solution, animals were monitored for 48 hours, and the number of dead animals was recorded at the end of the experiment. The dose that killed 50 percent animals (LD50) was calculated using probit analysis (8, 9, 20).

Horse immunization

The LD50 values determined in mice were selected to induce primary immune responses in horses. Increasing venom doses were used to induce and maintain secondary immune responses. Adjuvants were used to enhance immune responses. On the first day, 180 mg venom (macerated telsons), mixed half-and-half with Freund's Complete Adjuvant (FCA), was subcutaneously injected into horses for primary immunization, and on the 14th day, 360 mg venom, mixed half-and-half with Freund's Incomplete Adjuvant (FIA), was subcutaneously injected into horses for secondary immunization (v/v). To maintain immune responses, 720, 1,000, 1,000, and 1,500 mg venom, mixed with 0.5 ml of 0.4% aluminium phosphate (AIPO4 – v/0.5 ml), were subcutaneously injected into horses on the 21st, 28th, 35th, and 42nd days, respectively (Table 1). Thus, 4,760 mg telsons (approximately 238 pieces) were used for the hyperimmunization of one horse.

 

 

Immunization control

Before each venom injection, we verified the immune status of horses to assess their antibody (IgG) condition and to determine whether hyperimmunization could be performed.

On the 21st, 28th, 35th, and 42nd days, 5 ml blood samples were collected from the jugular vein of animals and stored in sterile bottles containing anticoagulants from the horses. After plasma separation, samples of each above-mentioned day were again stored in sterile bottles for determination of the ED50 (Figure 1). Neutralization was expressed as ED100. Immunization plan continued according to these potency results.

 

 

Antivenom production

On the 45th, 48th, and 51st days, 5 L blood samples were collected from the jugular vein of each animal for three times (15 L) and stored in containers with 10% sodium citrate. After plasma separation, 10 L antivenom was obtained from combined plasma (from 75 L blood in total) by the digestive method (15) and kept in the dark under 4°C.

Determination of the Effective Dose 50% (ED50)

To assess the antivenom potency, venom stock solution, at a dose 35-fold higher than the LD50 for one mouse, was separated in 6 tubes (0.7 ml each). Each tube received 0.3, 0.4, 0.5, 0.6, 0.7, and 0.8 ml, respectively, of the antivenom solution and had its volume completed to 3.5 ml with PSS. These solutions of different concentrations were incubated at 37°C for one hour for antigen-antibody reaction. Then, 0.5 ml of each solution was subcutaneously injected into a different group of mice (7 groups of 6 mice each); control group was subcutaneously injected with 0.5 ml venom solution (0.1 ml stock venom solution and 0.4 ml PSS; 5 LD50).

After injection, animals were monitored for 48 hours. The number of living animals was recorded, and the ED50 was calculated according to probit analysis (8, 9, 20).

 

RESULTS

The LD50 of venom prepared from macerated telsons was 1 ml/kg (95% confidence interval; 0.8-1.3). Since 1 ml venom contained 180 mg telsons, LD50 was also calculated as 180 mg/kg.The venom and adjuvants doses administered to horses were determined according to the LD50 in mice (Table 1).

Depending on the adjuvant utilized, aseptic abscess developed in the neck of horses during the immunization period, requiring local dressing.

We verified the changes in the horse sera neutralizing capacity against the LD50 of A. crassicauda venom. Serum antibody concentration decreased (4, 3, 2, 1.5 ml) as venom concentration (2, 3, 4, 5 LD50) increased (Figure 1). With 5 LD50 of venom, neutralization capacity of serum was 1.5 ml (ED100), whereas mice in the control group died.

Antivenom (10 L) was obtained from 75 L blood collected from horses after the administration of venom enriched with adjuvants. Its ED50, determined according to the probit method, was 0.5 ml (95% confidence interval; 0.40-0.58), which was capable of neutralizing a venom dose 35-fold higher than the LD50 for one mouse (LD50 = 3.6 mg telsons/mouse), being prepared in 51 days. Finally, only 238 telsons were needed for the immunization of one horse.

 

DISCUSSION

In this study, antivenom was produced in a short time with a small quantity of telsons. The LD50 obtained was 1 ml/kg. It was calculated that 3.6 mg telsons could kill a mouse of approximately 20 g. In other words, since 1 telson is about 20 mg, 18% of it corresponds to the LD50 for one mouse. This conclusion was similar to that of Ozkan and Filazi, who used the same species of scorpions and stated that 16% of one telson corresponded to the LD50 value for one mouse (13). However, Tulga, using the same scorpions species and methodology, reported that from 3.3% to 5% of one telson corresponded to the LD50 for one mouse (17).

Differences between scorpion venoms toxicities can be explained by different ways of collecting scorpions, changes in their physiologic status and feeding patterns. In addition, during capture and killing, scorpions could have used some venom to protect themselves, and factors such as telsons transporting conditions, drying method, storage and period of use could have influenced these differences too (13).

Scorpion venoms are neurotoxins of fatal and paralytic activity but with poor antigenic properties since they are composed of simple proteins of low molecular weight (6, 21). Therefore, during hyperimmunization, every producer employs different techniques to increase these properties and consequently stimulate the immune system, ensuring the formation of an adequate number of antibodies(16). For this purpose, the Algerian Pasteur Institute produced antivenom by adding penicillin and streptomycin to saline solution, which was used as venom diluter; Tulga added 50% of beef extract and 0.4% aluminium phosphate to venom solution(17). On the other hand, Mohamed et al. obtained antivenom by using purified picrate venom derived from telsons (11). In Turkey, production of scorpion antivenom by the Refik Saydam Hygiene Center (RSHC) utilizes beef extract and 4% aluminium phosphate for the immunization of horses (4). In the Lister Institute of Preventive Medicine (UK), antivenom is obtained by adding 1% of broth with peptone and 0.4% aluminium phosphate to the venom solutions prepared from macerated telsons (3). Despite the fact that today aluminum hydroxide (AlOH) or alginate is used as adjuvant in the production of antivenoms, it is suggested that using Freund's Complete Adjuvant (FCA) and Freund's Incomplete Adjuvant (FIA) would be more effective in increasing the immune response (16). In this study, FCA, FIA, and 0.4% aluminium phosphate were used as adjuvants in the production of antivenom.

To obtain venom from scorpions, methods such as maceration, manual techniques and electrical stimulation are applied. Maceration is one of the oldest and simplest methods based on the principle of keeping telsons of dead scorpions in physiologic saline solution (6, 7). To obtain an adequate amount of venom by this method, quite a few scorpions need to be killed. Venom obtained by this process is given to horses at increasing sublethal doses and antivenom is produced. The Algerian Pasteur Institute reported that one horse could be immunized against Androctonus australis venom by using 400-500 telsons (6). For the immunization of one horse, Tulga used 1,428 A. crassicauda macerated telsons, and this quantity may be increased from 1,500 to 2,000 to ensure an adequate hyperimmunization (18).

Today, in Turkey, venom obtained through maceration of telsons from A. crassicauda scorpions collected in the Southeastern Anatolia Region is used as antigen for the production of antivenom, and it is stated that the hyperimmunization of one horse requires from 1,500 to 2,000 telsons (4, 17, 18). In the present study, antivenom used for hyperimmunization of one horse was produced through maceration of approximately 238 A. crassicauda telsons.

The Algerian Pasteur Institute reported that to obtain an adequate immune response (produce antibodies), horses must be immunized for at least eight months (6). Tulga, on the other hand, produced antivenom in 100 days (17). In Turkey, according to the present antivenom production method used, 4-5 months are required for the hyperimmunization of one horse and consequently for the production of antivenom (17, 18). However, in this study, antivenom was produced in 51 days.

The European pharmacopoeia and the method mentioned in the technical reports of the World Health Organization (8, 20) were used during the determination of the potency of the antivenom produced in this study. We found out that 0.5 ml antivenom, which corresponded to 35 LD50 of the venom, protected 50% animals. Also, antivenom potency was studied based on the protocol used in the RSHC Biologic Control and Research Laboratory for A. crassicauda antivenom production (4, 5). It was observed that 0.2 ml of antivenom prepared this way neutralized 2 Minimal Lethal Dose (2 MLD) of venom in rats (2).

According to the present results, potent antivenom can be produced in 51 days using a smaller number of telsons. Thus, with less animals collected, especially from the Southeastern Anatolia Region, the regional scorpion fauna can be protected.

 

ACKNOWLEDGMENTS

We wish to thank Karina Chamma for her valuable comments on this manuscript.

 

REFERENCES

1 ALEXANDER JO'D. Scorpion stings. In: ALEXANDER JO'D. Ed. Arthropods and human skin. Berlin: Springer-Verlag, 1984: 199-207.        [ Links ]

2 ANDROCTONUS CRASSICAUDA ANTIVENOM POTENCY TEST PROCEDURE IN RATS. Biologic control and research laboratory (Laboratory textbook). 2004. 5.        [ Links ]

3 ANTIVENOM PRODUCTION PROCESS. Lister Institute of Preventive Medicine. Federal Security Agency U.S. Public Health Service National Institute of Health (Textbook). 1948. 161.        [ Links ]

4 ANTIVENOM PRODUCTION PROTOCOL. Scorpion antivenom production protocol used Refik Saydam Hygiene Center. 1956. 46.        [ Links ]

5 ANTIVENOM PROSPECTUS. Scorpion antivenom production prospectus used by Refik Saydam Hygiene Center of Turkish Republic Health Ministry. (Prospectus, using instruction). 2004. 2.        [ Links ]

6 BALOZET L. Scorpionism in the Old World. In: BÜCHERL W., BUCKLEY E. Eds. Venomous animals and their venoms. New York: Academic Express, 1971: 349-71.        [ Links ]

7 BÜCHERL W. Classification, biology and venom extraction of scorpion. In: BÜCHERL W., BUCKLEY E. Eds. Venomous animals and their venoms. New York: Academic Express, 1971: 317-47.        [ Links ]

8 EUROPEAN PHARMACOPOEIA. 3. ed. Strasbourg: Council of Europe, 1997. 1712-3. (European Treaty Series, 50)        [ Links ]

9 FINNEY DJ. Probit analysis. 3. ed. London: Cambridge University Press, 1971. 333p.        [ Links ]

10 ISBISTER GK., GRAUDINS A., WHITE J., WARRELL D. Antivenom treatment in arachnidism. J. Toxicol. Clin. Toxicol., 2003, 41, 291-300.        [ Links ]

11 MOHAMED AH., DARWISH MA., HANI-AYOBE M. Immunological studies on scorpion (B. quinquestriatus) antivenin. Toxicon, 1975, 13, 67-8.        [ Links ]

12 MULLEN G., STOCKWELL SA. Scorpions (Scorpiones). In: MULLEN G., DURDEN L. Eds. Medical and veterinary entomology. Amsterdam: Academic Press, 2002: 411-23.        [ Links ]

13 OZKAN O., FILAZI A. The determination of acute lethal dose-50 (LD50) levels of venom in mice, obtained by different methods from scorpions, Androctonus crassicauda (Oliver 1807). Acta Parasitol. Turcica, 2004, 28, 50-3.        [ Links ]

14 OZKAN O., KARAER Z. The scorpions in Turkey. Turk. Hig. Deney. Biyol. Derg., 2003, 60, 55-62.        [ Links ]

15 SEZGINMAN N., DEMIRTAS N. Purification and concentration of antitoxic sera. Turk. Hij. Tecr. Biyol. Derg., 1970, 30, 63-75.        [ Links ]

16 THEAKSTON RD., WARRELL DA., GRIFFITHS E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon, 2003, 41, 541-57.        [ Links ]

17 TULGA T. Cross reactions between anti-scorpion (Buthus quinquestriatus) and anti-scorpion (Prionurus crassicauda) sera. Turk. Hij. Deney. Biyol. Derg., 1960, 20, 191-203.        [ Links ]

18 TULGA T. Scorpions found in Turkey and paraspecific action of an antivenin produced with the venom of the species Androctonus crassicauda. Turk. Hij. Deney. Biyol. Derg., 1964, 24, 146-55.        [ Links ]

19 WHITTEMORE Jr. FW., KEEGAN HL., BOROWITZ JL. Studies of scorpion antivenins. Bull. World Health Organ., 1961, 25, 185-8.        [ Links ]

20 WORLD HEALTH ORGANIZATION. Requirement for snake antivenins. Geneva: World Health Organization, 1971. 21-44. (WHO Tech. Rep. Ser., 21)        [ Links ]

21 ZLOTKIN E., MIRANDA F., ROCHAT H. Chemistry and pharmacology of Buthinae scorpion venoms. In: BETTINI S. Ed. Handbook of experimental pharmacology. Berlin: Springer-Verlag, 1978: 317-29.        [ Links ]

 

 

Correspondence to:
Ozcan Ozkan
Poison Research Center
Refik Saydam Hygiene Center
Ankara, Turkey
Phone: 00-90-312-433 70 01. Fax: 00-90-312-433 70 00
Email: ozcanozkan_62@hotmail.com

Received: June 14, 2005
Accepted: October 18, 2005
Abstract published online: January 20, 2006
Full paper published online: August 31, 2006

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License